All Press Releases

ALL PRESS RELEASES 2019
May 31, 2019
Notice Of Annual General Meeting In Modus Therapeutics Holding AB (Publ) In Swedish >
May 13, 2019
Modus Therapeutics Announces The Results Of Its Global, Randomized, Placebo-Controlled Phase 2 Clinical Trial Evaluating Sevuparin For The Management Of Acute Vaso-Occlusive Crisis (VOC) In Patients With Sickle Cell Disease (SCD) >
Mar 11, 2019
Modus Therapeutics Strengthens Management Team With Appointment Of Mats Blom, MBA As CFO >
Feb 22, 2019
First Cohort Dosed In U.S. Phase 1 Study Of Subcutaneously Administered Sevuparin >
Jan 29, 2019
Modus Therapeutics Strengthens Board With Two Key Appointments >